Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $11 and keeps a Buy rating on the shares. The firm said its 2Q25 report was largely uneventful as TSHA-102’s pivotal REVEAL Part B study remains on track with site activations already in progress and patient enrollment expected to commence in 4Q25. They also note the company is now capitalized through Ph3 data following its May financing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Advances Rett Syndrome Trials
- Taysha Gene Therapies price target raised to $10 from $9 at Chardan
- Taysha Gene Therapies: Positive Outlook with Pivotal Study and Strong Financial Health Justifies Buy Rating
- Taysha Gene Therapies reports Q2 EPS (9c), consensus (8c)
- TSHA Earnings this Week: How Will it Perform?